000			03277cam a2200349 a 4500
003			EG-GiCUC
005			20250223032038.0
008			180903s2018 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.09.M.Sc.2018.Ma.E
100	0		_aMarwa Moustafa Youssef Ahmed Nassef
245	1	0	_aEffect of ACE inhibitor lisinopril on fructose - induced metabolic syndrome in rats exposed toionizing radiation / _cMarwa Moustafa Youssef Ahmed Nassef ; Supervised Mohammed F. Alyamany , Muhammad Y. Alshorbagy , Mahmoud H. Shabon
246	1	5	_aتأثيرمثبط إنزيم الأنجيوتنسين كونفرتين ليسينوبريل فى متلازمة الأيض المستحثة باستخدام الفركتوزفي الجرذان التي عرضت للإشعاع المؤين
260			_aCairo : _bMarwa Moustafa Youssef Ahmed Nassef , _c2018
300			_a240 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmacology and Toxicology
520			_aIntroduction: The prevalence of Metabolic Syndrome is increasing worldwide and associated with an increased risk of cardiovascular disease, meanwhile the use of ionizing radiation might be considered a two-edged sword as it has high benefits as well as dangerous harmful effects on human beings. Aim of work: This study is designed to determine the therapeutic effect of Lisinopril in minimizing radiation-induced injuries in rats with fructose induced metabolic syndrome. Study Design: Rats were divided into 7 groups, each consisting of 15 rats. Control (CTR) animals had free access to ordinary tap water, Radiation (RAD) animals exposed to total body gamma irradiation of 1 GY every 4 weeks starting from week zero up to week 20, Fructose (FRC) animals provided with 10% fructose solution to drink ad libitum for 20 weeks, Radiation Fructose (RF) animals exposed to total body gamma irradiation of 1 GY every 4 weeks starting from week zero up to week 20 and provided with 10% fructose solution ad libitum for 20 weeks. Lisinopril (LIS) treated groups were administered 10mg/kg/day orally during the last 4 weeks of the experiment (week 17-20). Parameters measured: Systolic blood pressure, Body weight gain, Glucose levels, Insulin levels, Insulin resistance, Insulin sensitivity, ß-cell function, Intraperitoneal glucose tolerance test, Triglycerides, Total cholesterol, High density lipoproteins, Very low density lipoproteins, Low density lipoproteins, TG/HDL ratio, TC/HDL ratio, Thiobarbituric acid reactive substances, Reduced Glutathione (GSH), Uric acid, Creatinine, Alanine aminotransferase (ALT) activity and Aspartate aminotransferase (AST) activity, Interleukin-1beta (IL-1Ý) and tumor necrosis factor alfa (TNF-Ü)
530			_aIssued also as CD
653		4	_aACE inhibitor
653		4	_aLisinopril
653		4	_aMetabolic syndrome
700	0		_aMahmoud H. Shabon , _eSupervisor
700	0		_aMohammed F. Alyamany , _eSupervisor
700	0		_aMuhammad Y. Alshorbagy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aShimaa _eCataloger
942			_2ddc _cTH
999			_c67280 _d67280